MedTrace Logo

The Long COVID Treatment Trial

NCT07128082 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2025-12-23

No results posted yet for this study

Summary

The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that has no medication. Participants will take the medication (or placebo) they are given and complete study surveys for 12 months. All of the study tasks are done remotely from the comfort of a participants home.

Conditions

Interventions

DRUG

Tirzepatide

The treatment group will receive the study medication (tirzepatide) for a 12 month period starting with a 2.5mg dose once a week.

DRUG

Placebo

Participants in the control group will receive a placebo instead of active study medication for a 12 month period.

Sponsors & Collaborators

  • Schmidt Initiative for Long COVID

    collaborator UNKNOWN

  • Scripps Translational Science Institute

    lead OTHER

Principal Investigators

  • Julia Moore Vogel · Scripps Translational Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-30
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07128082 on ClinicalTrials.gov